Press Releases

Biostage to Present at the 2017 Cell & Gene Meeting on the Mesa
- Presentation with live video webcast Thursday, October 5th at 4:45PM PDT -

HOLLISTON, Mass., Oct. 2, 2017 /PRNewswire/ -- Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced today that Saverio La Francesca, MD, President and Chief Medical Officer of Biostage, will present at the 2017 Cell & Gene Meeting on the Mesa on Thursday, October 5th at 4:45PM PDT in La Jolla, CA. Members of the executive management team will also participate in one-on-one meetings during the conference.

BSTG Logo

Dr. La Francesca will provide a medical and scientific review as well as outline the Company's expected upcoming near-term corporate, clinical and regulatory milestones that will enable Biostage's transition to a clinical-stage company.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (www.biostage.com).

About the Cell & Gene Meeting on the Mesa
Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The event's Partnering Forum on October 4-5, features more than 70 dedicated company presentations in addition to 90 panelists and featured speakers.

Please visit http://www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at lparsons@alliancerm.org and interested media should contact Lyndsey Scull at lscull@alliancerm.org.

About Biostage
Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

For more information, please visit www.biostage.com and connect with the Company on Twitter and LinkedIn.

Forward-Looking Statements:
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the private placement, any rights offerings, development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which closings, offerings, expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing our Cellframe technology, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products and our ability to complete the private placement on a timely basis or at all; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:  


Tom McNaughton                      


Chief Financial Officer                 


774-233-7300                              


tmcnaughton@biostage.com         


SOURCE Biostage Inc.


print email pdf rss